A clinical investigation into PTC299, an oral dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19* is discussed in this PTC-sponsored webinar from 2020
Webinar: Scientific updates on investigation of small molecules in patients with COVID-19
GL-CORP-0207 | June 2021
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.